Last edition
News about "metastatic breast cancer "
Lupin and Natco Secure USFDA Approval for Generic Cancer Drug Eribulin Mesylate Injection
Lupin and Natco Pharma have received USFDA approval for Eribulin Mesylate Injection, a generic equivalent of Halaven, used in the treatment of advanced breast cancer and liposarcoma.
Metastatic Breast Cancer | 03/06/2026 | By News Bureau
Biotheryx Doses First Patient in Dose Expansion Trial of BTX-9341 for Advanced Breast Cancer
Biotheryx advances BTX-9341 into a dose expansion trial with fulvestrant for HR+/HER2- breast cancer, aiming to overcome resistance in patients previously treated with CDK4/6 inhibitors.
Metastatic Breast Cancer | 19/03/2026 | By News Bureau | 139
The UK regulator has approved Inluriyo (imlunestrant tosylate) for adults with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations after prior hormone therapy failure.
Metastatic Breast Cancer | 26/02/2026 | By News Bureau | 170
Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer
Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />
Metastatic Breast Cancer | 08/10/2025 | By Dineshwori | 542
Roche Reports Positive Results from Phase III evERA Breast Cancer Study
Roche has announced positive results from the phase III evERA study evaluating its investigational oral selective oestrogen receptor degrader (SERD), giredestrant, in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Metastatic Breast Cancer | 24/09/2025 | By Dineshwori | 182
Novartis Reports Double-Digit Sales Growth In Q2, Raises Full-Year Guidance
Novartis has reported a robust financial performance for the second quarter of 2025, with net sales reaching USD 14.1 billion, up 12 percent year-on-year.
Metastatic Breast Cancer | 17/07/2025 | By Dineshwori | 1256
Zydus Gets Approval from COFEPRIS to Market Mamitra
Zydus Lifesciences has announced that COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) has granted marketing approval for Mamitra, a Trastuzumab biosimilar.
Metastatic Breast Cancer | 31/07/2024 | By Aishwarya | 836
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy